{"doi":"10.1002/mdc3.13763","title":"Memantine Use and Cognitive Decline in Huntington's Disease: An <scp>Enroll‐HD</scp> Study","abstract":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Memantine is an <jats:italic>N</jats:italic>‐methyl‐<jats:italic>d</jats:italic>‐aspartate (NMDA) receptor antagonist that is used to treat moderate to severe Alzheimer's Dementia (AD) and has been speculated to provide clinical benefits in Huntington's disease (HD).</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>To assess the effectiveness of memantine on the trajectory of cognitive decline in individuals with manifest HD.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Using participants from the Enroll‐HD study, the primary analysis compared trajectories in cognition over a 5‐year period using linear mixed effect models of prevalent and incident memantine users who were propensity‐score‐matched with non‐users on measures of disease progression and demographics.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>In the primary analysis there were no significant differences in the trajectories between memantine users and non‐users on any primary outcomes of interest.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Memantine use was not associated with any clinical benefit for individuals with manifest HD. Further studies are warranted to assess the impact of memantine on clinical outcomes in HD.</jats:p></jats:sec>","journal":"Movement Disorders Clinical Practice","year":2023,"id":640677,"datarank":0.3596842909197557,"base_score":2.3978952727983707,"endowment":2.3978952727983707,"self_citation_contribution":0.3596842909197557,"citation_network_contribution":0.0,"self_endowment_contribution":0.3596842909197557,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":10,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":667654,"name":"Jordan L. Schultz","orcid":"0000-0002-0985-7268","position":1,"is_corresponding":false},{"id":1149272,"name":"Amy C. Ogilvie","orcid":"0000-0003-4399-2946","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Memantine Use and Cognitive Decline in Huntington's Disease: An Enroll-HD Study.","abstract":"<h4>Background</h4>Memantine is an <i>N</i>-methyl-<i>d</i>-aspartate (NMDA) receptor antagonist that is used to treat moderate to severe Alzheimer's Dementia (AD) and has been speculated to provide clinical benefits in Huntington's disease (HD).<h4>Objective</h4>To assess the effectiveness of memantine on the trajectory of cognitive decline in individuals with manifest HD.<h4>Methods</h4>Using participants from the Enroll-HD study, the primary analysis compared trajectories in cognition over a 5-year period using linear mixed effect models of prevalent and incident memantine users who were propensity-score-matched with non-users on measures of disease progression and demographics.<h4>Results</h4>In the primary analysis there were no significant differences in the trajectories between memantine users and non-users on any primary outcomes of interest.<h4>Conclusions</h4>Memantine use was not associated with any clinical benefit for individuals with manifest HD. Further studies are warranted to assess the impact of memantine on clinical outcomes in HD.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"37476323","pmcid":"PMC10354618","openalex_id":null,"authors":[],"funders":[{"funder_name":"NINDS NIH HHS","grant_id":"K23 NS117736","title":null}],"total_grants":1,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"hybrid","license":"cc-by","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.13763","host_type":"publisher"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10354618/pdf/MDC3-10-1120.pdf","host_type":"repository"},{"url":"https://doi.org/10.1002/mdc3.13763","host_type":"Unpaywall"},{"url":"https://europepmc.org/articles/PMC10354618","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC10354618?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":[],"mesh_terms":[],"keywords":["Cognition","Memantine","Huntington's disease","Progression"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T13:15:08.013689Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}